Список литературы:

Поставить закладку

Bansal N, Zelnick LR, Alonso A, et al. eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atheroscle- rosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol 2017;12:1386–1398.177.
Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrilla- tion (ATRIA) study. Circulation 2009;119:1363–1369.178.
Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102–1107. 179.
Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J 2009;158:629–636.
Jonsson K.M., Wieloch M., Sterner G. et al. Glomerular filtra- tion rate in patients with atrial fibrillation on warfarin treat- ment: a subgroup analysis from the AURICULA registry in Sweden. Thromb Res 2011;128:341–345. doi: 10.1016/j. thromres.2011.04.022.
Лукьянов М.М., Бойцов С.А., Якушин C.C. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбула- торно-поликлинической практики (по данным РЕгистра КардиоВАскулярных ЗАболеваний РЕКВАЗА) Рациональная Фармакотерапия в Кардиологии. 2014; 10(4): 366–377.
Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20:705–711.
Steffel J, Hindricks G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. Eur Heart J 2012;33:2766–2768.
Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. Published online ahead of print. doi:10.1093/eurheartj/ehw210.
Мухин Н. А., Смирнов А. В., Кобалава Ж. Д., Бобкова И. Н., Виллевальде С. В., Козловская Л. В. и др. Сердечно- Сосудистый Риск И Хроническая Болезнь Почек: Стратегии Кардио-Нефропротекции. Российский Кардиоло- гический Журнал. 2014;8 (112):7–37.
Рабочая группа Научного общества нефрологов России. Национальные рекомендации. Хроническая болезнь почек: основные положения, определение, диагностика, скрининг, подходы к профилактике и лечению. Санкт-Петербург: Левша;2012. 52 с.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16 (1):31–41.
Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–163.
Pisters R, Lane DA, Nieuwlaat R et al. A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation // Chest. 2010. Vol. 138, № 5. P. 1093–1100.
Клинические рекомендации «Диагностика и лечение фибрилляции предсердий» Всероссийского Научного Общества специалистов по клинической электрофизи- ологии, Аритмологии и электрокардиостимуляции (ВНОА) в сотрудничестве с Российским Кардиологическим обществом (РКО) и Ассоциации сердечно-сосудистых хирургов России (АССХ). 2017 год
Cranenburg E.C.M. et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification // J. Vasc. Res. 2008. Vol. 45, № 5. P. 427–436.
Yang F. et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease // Heart Br. Card. Soc. 2017. Vol. 103, № 11. P. 818–826.
Brodsky SV, Satoskar A, Chen J, Nadasdy G, Eagen JW, Hamirani M et al. Acute Kidney Injury During Warfarin Therapy Associated With Obstructive Tubular Red Blood Cell Casts: A Report of 9 Cases. American Journal of Kidney Diseases. 2009;54 (6):1121–6.
Инструкция по применению лекарственного препарата для медицинского применения Ксарелто® 15 / 20 мг ЛП-001457 [Интернет]. [цитируется по 15 август 2018 г.]. Доступно на: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=a80355f3-299b-4ff2-ac03- 2ba27235c453&t=
Инструкция по применению лекарственного препарата для медицинского применения Эликвис® ЛП-002007 [Интернет].[цитируется по 15 август 2018 г.]. Доступно на: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=de6b807f-2bf4-4fb2-b083- 6b77e859f090&t=
Инструкция по применению лекарственного препарата для медицинского применения Прадакса® ЛП-000872 [Интернет]. [цитируется по 15 август 2018 г.]. Доступно на: https://grls.rosminzdrav.ru/Grls_ View_v2.aspx?routingGuid=4c9b50d6-b4e8-40d4-8d9b- bd386b1a6578&t=
Patel M.R. et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011; 365(10):883–891.
Connolly S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): 1139–1151. Granger C.B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–992.
Fox K.A.A. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal. 2011; 32: 2387–2394.
Hohnloser S.H. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal. 2012; 33: 2821–2830.
Hijazi Z. et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation. 2014; 129: 961–970.
Mueck W, Lensing AW, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep- vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675–686.
Weinstein J.R., Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010 Jul; 17(4): 302–307
Fordyce C.B., Hellkamp A.S, Lokhnygina Y. et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. Circulation. 2016;134:37-47.
Bohm M., Ezekowitz M.D., Connolly S.J. et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.J Am Coll Cardiol 2015;65:2481–2493
Hijazi Z, Hohnloser S.H., Andersson U. et al. Efficacy and Safety of Apixaban Compared WithWarfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016;1(4):451-460
Yao X., Tangri N., Gersh B.J. et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol 2017;70:2621–2632 34. Steffel J, Verhamme P, Potpara T.S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, Volume 39, Issue 16, 21 April 2018, Pages 1330–1393
Piccini JP et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/ CIRCULATIONAHA.112.107128

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница